Value of Biosimilars in Women’s Health Roundtable Series
Watch the webinars!
25 Feb 2021
03 Apr 2024
ProgramsBiosimilars are powerful, life-changing medicines. Many chronic, debilitating autoimmune diseases that affect women in greater numbers than men, such as lupus or rheumatoid arthritis, can be treated with biosimilars, as can breast cancer and many other conditions. But, despite the potential benefits, a HealthyWomen survey found that 70% of respondents don't understand biosimilars.
While biosimilars have been available for nearly 15 years in Europe and other countries, the first one wasn't approved in the United States until 2015. Although the U.S. Food and Drug Administration has since approved 29 biosimilars, just a handful are on the market and the potential cost savings have not been realized.
To explore biosimilars and what they can mean for women's health, HealthyWomen put together an engaging webinar series with diverse experts for robust discussions on innovations in biosimilars, overcoming challenges and barriers to accessing biosimilars, and what women need to know about the latest treatment options.
Read the report: Value of Biosimilars in Women's Health
Explore our timely topics below
What Women Need To Know About Biosimilars as the Latest Treatment Options
Biosimilars may be more affordable than the drugs they're modeled after — and they work just as well. Could they be an option for you?
Watch the video
Moderator: Alisa Vidulich, MPH, Policy Director, Arthritis Foundation
Panelists:
- Sarah Ikenberry, Senior Communication Advisor, Office of Therapeutic Biologics and Biosimilars, CDER, FDA
- Brooke Abbott, Patient Thought Leader, Crohn's & Colitis Foundation and Founder of crazycreolemommy.com
- Pam Traxel, Senior Vice President, American Cancer Society Cancer Action Network (ACS CAN)
What Providers Need To Know To Use Biosimilars As Treatment Options
Biosimilars may be the right treatment option for your patients. But how do you know if and when to recommend them?
Watch the video
Moderator: Sameer Awsare, M.D., FACP, Associate Executive Director, The Kaiser Permanente Medical Group
Panelists:
- Dennis Cryer, M.D., Biologics Prescribers Collaborative
- Angus Worthing, M.D., Arthritis & Rheumatism Associates, Clinical Assistant Professor of Medicine (Rheumatology), Georgetown University Medical Center
- Stacy Elder Dalpoas, Pharm.D, MPH, Clinical Pharmacy Manager, Novant Health
Innovations in Treatment through Biosimilars
Learn where are we are today with biosimilar development in the United States and what new treatment options are on the horizon for various diseases and conditions.
Watch the video
Moderator: Meaghan Smith, Executive Director, Biosimilars Forum
Panelists:
- Chad Pettit, Executive Director, Marketing, Global Biosimilars Commercial Lead, Amgen
- James Carey, AVP, Health Policy, Merck
- Erika Satterwhite, Head of Global Policy, Viatris
- Juliana Reed, Pfizer Biosimilars, President, Biosimilars Forum
Thank you to our supporters, Amgen and Viatris.
Learn more
From Your Site Articles
- Questions About Biosimilars - HealthyWomen ›
- Barriers to Biosimilars in the US - HealthyWomen ›
- Clinically Speaking: What Are Biosimilars? - HealthyWomen ›
- Women Need Biosimilars - HealthyWomen ›
- Coming Soon to a Pharmacy Near You: Biosimilars - HealthyWomen ›
- Preguntas sobre biosimilares - HealthyWomen ›
- Obstáculos de los biosimilares en EE.UU. - HealthyWomen ›
ADVERTISEMENT
Everything you need to know about women’s health — in one place.